<DOC>
	<DOCNO>NCT00185302</DOCNO>
	<brief_summary>Primary objective : To evaluate efficacy two different dose schedule MS-275 subject metastatic melanoma Secondary objective : To evaluate safety assess pharmacokinetic profile MS-275 subject metastatic melanoma</brief_summary>
	<brief_title>Safety Efficacy Study New Chemotherapy Agent Treat Metastatic Melanoma</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<criteria>Adult subject Stage III IV nonresectable nonuveal ( cutaneous mucosal ) metastatic melanoma receive least one two previous systemic therapy ( immunotherapy and/or chemotherapy ) metastatic disease respond progressed recent therapy eligible enrollment Presence least one lesion fulfil minimum Response Evaluation Criteria Solid Tumors ( RECIST ) size requirement target lesion Use highly effective birth control method female childbearing potential Able undergo either contrast enhance compute tomography ( CT ) scan contrast enhance magnetic resonance imaging ( MRI ) scan tumor assessment Life expectancy great 3 month Adequate organ bone marrow function define : absolute neutrophil count ≥ 1500 /µL , platelet ≥ 100,000 /µL , creatinine ≤ 1.5 × upper limit normal ( ULN ) measure creatinine clearance ≥ 60 mL/min x 1.73 m2 body surface area , total bilirubin ≤ 1.5 time ULN , aspartate aminotransferase serum glutamic oxalacetic transaminase/alanine aminotransferase serum glutamic pyruvic transaminase∗ ≤ 2.5 time ULN Negative serum pregnancy test within 2 week prior receive first dose study drug female subject childbearing potential . Agreement use highly effective method birth control throughout study period 3 month thereafter sexually active male female childbearing potentia Active malignancy last five year Pregnancy , breast feeding HIV infection Brain metastasis Concomitant use corticosteroid valproic acid Uncontrolled intercurrent illness Diagnosis uveal melanoma Eastern Cooperative Oncology Group performance status ≥ 2 Ongoing effect previous investigational drug study concomitant participation investigational drug study Prior use MS275 HDAC inhibitor History allergic reaction attribute compound similar chemical biologic composition MS275 Anticancer therapy Active gastrointestinal condition might predispose poor drug absorption Major surgery within 4 week prior enrollment Hypophosphatemia &lt; 2.5 mg/dL screening , correct screening period Medical , psychiatric condition compromise patient 's ability understand patient information , give informed consent , comply trial protocol , complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Non-resectable metastatic melanoma</keyword>
</DOC>